Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

NCT03921879 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Lymphoma, T-Cell
Lymphoma, Follicular
Lymphoma, Peripheral T-Cell
Lymphoma, Hodgkin

Interventions

DRUG: OT-82 Dose Escalation
DRUG: OT-82 Dose Expansion

Sponsor

Oncotartis, Inc.